{"title":"降低心血管事件的风险","authors":"S. Chaplin","doi":"10.1002/psb.2045","DOIUrl":null,"url":null,"abstract":"Icosapent ethyl (Vazkepa) is an omega‐3 fatty acid prodrug indicated for reducing the risk of cardiovascular events in statin‐treated patients. This article summarises the clinical trial evidence for its efficacy and its place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Icosapent ethyl for reducing the risk of cardiovascular events\",\"authors\":\"S. Chaplin\",\"doi\":\"10.1002/psb.2045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Icosapent ethyl (Vazkepa) is an omega‐3 fatty acid prodrug indicated for reducing the risk of cardiovascular events in statin‐treated patients. This article summarises the clinical trial evidence for its efficacy and its place in therapy.\",\"PeriodicalId\":88184,\"journal\":{\"name\":\"The Prescriber\",\"volume\":\"15 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/psb.2045\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Icosapent ethyl for reducing the risk of cardiovascular events
Icosapent ethyl (Vazkepa) is an omega‐3 fatty acid prodrug indicated for reducing the risk of cardiovascular events in statin‐treated patients. This article summarises the clinical trial evidence for its efficacy and its place in therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
